Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Tuesday, May 15, 2012

National Campaign Aims to End Hepatitis B in High-Risk Asian American and Pacific Islander Populations

The Association of Asian Pacific Community Health Organizations (AAPCHO) and the Hepatitis B Foundation, with the support of the U.S. Department of Health and Human Services’ Office of Minority Health, today launched the “Hep B United” national campaign aimed at bringing attention and action to ending hepatitis B, especially among high-risk Asian American and Pacific Islander (AAPI) populations in the U.S.

Chronic hepatitis B is a liver disease caused by the hepatitis B virus (HBV) and is widely known as a “silent killer” because it can slowly destroy the liver without causing noticeable symptoms. More than half of the estimated 2 million people infected with HBV in the U.S. are AAPI. The primary goal of Hep B United is to support the success of community-based groups across the U.S. working to increase hepatitis B awareness, screening, vaccination, and access to care and treatment for all Americans, particularly AAPI populations disproportionately impacted by the disease.

Read more....

No comments:

Post a Comment